Melanoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 16 years or older
- People who have been diagnosed with stage III melanoma (specifically stage IIIB, IIIC, or IIID) that has spread to one or more nearby lymph nodes, confirmed by laboratory testing of tissue samples
- People whose melanoma is considered surgically removable (resectable) and has measurable tumour spread visible on scans or physical examination
- People whose lymph node involvement meets at least one of these descriptions: a lymph node that can be felt by touch and confirmed as melanoma; a lymph node that cannot be felt but appears enlarged on imaging scans and is confirmed as melanoma; or a lymph node that shows up on a PET scan and is confirmed as melanoma
- People whose tumour burden (overall amount of cancer present) is considered appropriate for pre-surgery immune therapy treatment, according to standard medical practice
- People for whom a procedure to mark the affected lymph node before surgery (called ILN marking) is technically possible (confirm with trial site)
- People who are willing and able to provide written consent to participate
Who may not be able to join:
- People whose melanoma originated in the eye (uveal or ocular melanoma) or in the mucous membranes (mucosal melanoma)
- People with a WHO performance status score of 2 or higher, meaning their cancer significantly limits their daily activities (confirm with trial site)
- People whose melanoma has only spread through the skin tissue between the original tumour and nearby lymph nodes (called in-transit metastases), without confirmed lymph node involvement
- People who have previously received targeted therapy drugs aimed at the BRAF or MEK proteins for their melanoma
- People who have previously received immunotherapy drugs targeting CTLA-4, PD-1, or PD-L1 for their melanoma
- People who have a current or past diagnosis of melanoma that has spread to distant parts of the body (stage IV melanoma)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +31 10 704 19 02
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Local Recurrence Free Survival (LRFS); Distant Metastasis Free Survival (DMFS)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.